About Contact Us Careers

Hemophilia A Drugs Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 2422
Published Date: Oct 09, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Hemophilia A Treatment Landscape

Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Takeda Pharmaceutical Company Limited
F. Hoffmann-La Roche Ltd
Novo Nordisk A/S
Genzyme Corporation
Grifols, S.A.
CSL Behring
Octapharma AG
Aptevo Therapeutics
Ferring Pharmaceuticals

Browse Key Market Insights with Data Illustration:

Hemophilia A Treatment Market Size & Share, Growth Report 2036

In the News

On April 1, 2020, the U.S. Food and Drug Administration approved Sevenfact [coagulation factor VIIa (recombinant)-jncw], a drug containing a recombinant analog of human FVII as the active ingredient, for the treatment as well as control of bleeding in people above the age of 12 with hemophilia A or B.

Author Credits: Radhika Pawar

Report ID: 2422
Published Date: Oct 09, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising cases of hemophilia A and growing awareness among people about the requirement for effective drugs for treatment are major factors driving the market growth.

The market is anticipated to attain a significant CAGR over the forecast period, i.e. 2020-2028.

Asia Pacific is estimated to provide more business opportunities for growth as a result of rising number of patients with hemophilia A and growing awareness about the need for preventing and treating hemophilia.

The major players in the market are Pfizer Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Genzyme Corporation, Grifols, S.A., CSL Behring, Octapharma AG, Aptevo Therapeutics and Ferring Pharmaceuticals.

Inquiry Before Buying Request Free Sample